Akero ’s NASH candidate reduces liver fat in patients taking a GLP-1

Akero Ther­a­peu­tics said its NASH drug re­duced liv­er fat in pa­tients who were al­so tak­ing a GLP-1 ag­o­nist. The NASH-fo­cused biotech on Mon­day re­leased topline da­ta from a Phase IIb tri­al for 32 pa­tients with type 2 di­a­betes and F1-F3 liv­er fi­bro­sis due to NASH who…#glp1 #nash #2diabetes #f1f3 #symmetry #f1 #f3 #unlock
Source: Reuters: Health - Category: Consumer Health News Source Type: news